GlassScriptPhysician profile
David S Overstreet
NPI 1659331049
$4,139.54
in general payments reported to CMS, 2019-2025
39 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $223 · 2021: $47.23 · 2022: $522 · 2023: $921 · 2024: $829 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,952.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $480.18 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $443.10 | 2019-2025 | |
| Amgen INC. | $298.18 | 2023-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $283.96 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $249.94 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $230.10 | 2022-2025 | |
| Abbott Laboratories | $222.33 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $213.34 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $159.86 | 2022 | |
| Sumitomo Pharma America, INC. | $157.38 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.47 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $136.00 | 2019-2024 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $115.09 | 2019-2023 | Livalo, Seglentis |
| Phathom Pharmaceuticals, INC. | $109.76 | 2023-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $101.34 | 2019-2023 | Verquvo, Steglatro, Lagevrio |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Overstreet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.